What Clinical Evidence Shows About Weight Loss Results
Clinical Weight Loss Evidence: Wegovy or Mounjaro for Weight Loss
When evaluating Wegovy or Mounjaro for weight loss, the clinical evidence provides the most reliable foundation for understanding potential results in UK patients. Wegovy's STEP clinical trial programme enrolled over 4,500 participants, with the landmark STEP 1 trial demonstrating that patients taking semaglutide alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks. The SELECT cardiovascular outcomes trial further showed a 20% reduction in major cardiovascular events, highlighting benefits beyond weight management alone.
Mounjaro's clinical programme, while impressive, used different trial designs and patient populations, making direct percentage comparisons inappropriate and potentially misleading. What we can say definitively is that both medications work through hormone pathways that regulate appetite and satiety, with Wegovy targeting GLP-1 receptors specifically, whilst Mounjaro acts as a dual GIP and GLP-1 receptor agonist. Both Wegovy and Mounjaro are available from EverydayMeds, where your prescriber can help determine which mechanism might be most appropriate for your individual circumstances.
UK Pricing and Value for Wegovy or Mounjaro Weight Loss Treatment
Understanding the investment required for either Wegovy or Mounjaro for weight loss helps UK patients plan their treatment journey effectively. Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose at £209.99 per pen. New customers can apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these transparent prices. Our bundle options provide convenience rather than savings, with the Progress Duo (0.5mg & 1mg) at £189.99 offering two months of treatment in a single order.
Mounjaro pricing follows a different structure reflecting its distinct dosing schedule and supply chain considerations. The key advantage when choosing between Wegovy or Mounjaro for weight loss at EverydayMeds lies in our comprehensive clinical support, GPhC-registered pharmacy standards (#9012878), and transparent pricing without hidden fees. Both treatments require the same rigorous 3-minute clinical assessment and prescriber review process, ensuring safety standards regardless of which prescription-only medicine your clinician recommends for your weight management journey.
STEP Trial Results: What Wegovy Weight Loss Evidence Shows
The STEP clinical trial programme provides robust evidence for Wegovy's weight loss potential when used alongside lifestyle modifications. STEP 1, published by Wilding et al. in the New England Journal of Medicine (2021), demonstrated that patients taking Wegovy achieved approximately 15% average weight loss compared to 2.4% with placebo at 68 weeks. STEP 3 combined Wegovy with intensive behavioural therapy, showing approximately 16% average weight loss, whilst STEP 5 confirmed sustainability with clinically studied weight loss maintained at two years.
These results specifically applied to adults with BMI ≥30 or BMI ≥27 with weight-related health conditions, matching the MHRA-licensed indication for UK patients. When considering Wegovy or Mounjaro for weight loss, it's essential to understand that these percentages represent averages from controlled clinical trials, and individual results will vary based on adherence, lifestyle factors, and personal health circumstances.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone involved in appetite regulation and blood sugar control. When considering Wegovy or Mounjaro for weight loss, understanding this mechanism helps explain why patients often experience reduced appetite and increased feelings of fullness after smaller meals. The medication works primarily in the brain's appetite centres, potentially reducing food cravings and helping patients adhere to reduced-calorie diets more effectively. Unlike Mounjaro's dual hormone approach, Wegovy focuses specifically on GLP-1 pathways, which have been extensively studied in the context of weight management. This targeted approach, combined with increased physical activity, forms the foundation of Wegovy's clinical effectiveness demonstrated in the STEP trial programme.
EverydayMeds Ordering Process for Weight Loss Treatment
Accessing either Wegovy or Mounjaro for weight loss through EverydayMeds begins with our 3-minute online clinical assessment, designed to evaluate your suitability for prescription-only weight management medications. Your responses undergo review by our qualified prescribers within 3 working days (or 24 hours with our express service), ensuring thorough evaluation of your medical history, current medications, and treatment goals. Once approved, your medication ships via next-day delivery using cold-chain, temperature-controlled packaging to maintain medication integrity from our GPhC-registered pharmacy (#9012878) directly to your door. Our clinical team remains available throughout your treatment journey to address questions about dosing, storage, or side effect management. This comprehensive support structure ensures you receive not just medication, but ongoing clinical guidance essential for successful weight management outcomes.
Storage and Practical Considerations: Wegovy vs Mounjaro
When comparing Wegovy or Mounjaro for weight loss, practical storage requirements can influence your choice, particularly for UK patients who travel frequently or have limited refrigerator space. Wegovy offers superior storage flexibility, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both medications require refrigerated storage at 2-8°C before first use, but Wegovy's extended room temperature stability provides greater convenience for holidays, business travel, or temporary storage challenges. The FlexTouch pen device used for Wegovy injections features a user-friendly design with dose escalation following a structured schedule: 0.25mg for weeks 1-4, progressing monthly through 0.5mg, 1mg, 1.7mg, to the maintenance 2.4mg dose. This systematic approach cannot be accelerated, ensuring your body adapts gradually to the medication's effects.
UK Patient Outcomes: Real-World Wegovy or Mounjaro Weight Loss Results
Real-world evidence from UK patients using either Wegovy or Mounjaro for weight loss demonstrates outcomes that often align closely with clinical trial data when patients maintain consistent adherence to prescribed dosing and lifestyle modifications. The National Institute for Health and Care Excellence (NICE) recommendation TA875 specifically endorses Wegovy for weight management when provided alongside specialist weight management support, reflecting confidence in its clinical effectiveness within the NHS framework. Patient feedback through EverydayMeds consistently highlights the importance of managing initial side effects during dose escalation, with most patients finding these diminish significantly as their body adapts to treatment.
Long-term sustainability remains a crucial consideration when choosing between Wegovy or Mounjaro for weight loss, with STEP 1 extension data showing patients regained approximately two-thirds of lost weight within one year of stopping treatment. This emphasises that weight management represents a long-term commitment rather than a short-term intervention, influencing treatment selection, duration planning, and ongoing clinical support requirements for optimal outcomes in UK patients.
Making Your Choice: Wegovy or Mounjaro for Weight Loss Success
Your decision between Wegovy or Mounjaro for weight loss ultimately depends on individual factors including your medical history, lifestyle requirements, storage needs, and prescriber recommendations following clinical assessment. EverydayMeds provides access to both options with identical clinical support standards, transparent pricing, and ongoing medication management to ensure your chosen treatment delivers optimal results. Our 3-minute assessment evaluates your suitability for either prescription-only medicine, whilst our qualified prescribers determine which mechanism—Wegovy's focused GLP-1 approach or Mounjaro's dual hormone strategy—best matches your clinical profile and weight management goals. Starting your journey is straightforward: complete our clinical assessment, apply discount code FIRST40 at checkout for new customers, and receive your prescribed treatment via next-day delivery with comprehensive support throughout your weight loss journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
